New Concepts and Pathophysiology of Lower Urinary Tract Symptoms in Men

European Urology, Supplements

Volumn 9, Issue 4, 2010, Pages 472-476

  Cruz, Francisco ^a   Desgrandchamps, François ^b  

^a University of Porto   (Portugal)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Bladder; BOO; Detrusor overactivity; LUTS; Metabolic syndrome; Prostate

Indexed keywords

ACETYLCHOLINE; NERVE GROWTH FACTOR;

ADRENERGIC STIMULATION; ARTICLE; BLADDER CONTRACTION; BLADDER FUNCTION; BLADDER OBSTRUCTION; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; HUMAN; HYPOTESTOSTERONEMIA; LOWER URINARY TRACT SYMPTOM; MALE; METABOLIC SYNDROME X; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK FACTOR; URINARY TRACT DISEASE;

EID: 77952878477     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.04.003     Document Type: Article

References (41)

1. Neal D.E., Ramsden P.D., Sharples L., et al. Outcome of elective prostatectomy. BMJ 299 (1989) 762-767
2. Thomas A.W., Cannon A., Bartlett E., Ellis-Jones J., and Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of transurethral resection of prostate for bladder outlet obstruction. J Urol 174 (2005) 1887-1891
3. Oelke M., Baard J., Wijkstra H., de la Rosette J.J., Jonas U., and Höfner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 54 (2008) 419-426
4. Hampel C., Dolber P.C., Smith M.P., et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 167 (2002) 1513-1521
5. Nomiya M., and Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170 (2003) 649-653
6. Kawabe K., Yoshida M., Homma Y., and Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98 (2006) 1019-1024
7. Yokoyama O, Ito H, Aoki Y, Oyama N, Miwa Y, Akino H. Selective alpha(1A)-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity. World J Urol. In press. doi:10.1007/s00345-009-0481-2.
8. Bing W., Chang S., Hypolite J.A., et al. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 285 (2003) F990-F997
9. Rajasekaran M., Wilkes N., Kuntz S., and E Albo M. Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats. Neurourol Urodyn 24 (2005) 295-300
10. Brading A.F. A myogenic basis for the overactive bladder. Urology 50 6A Suppl (1997) 57-67
11. Levin R.M., Haugaard N., O'Connor L., et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn 19 (2000) 609-629
12. Schröder A., Chichester P., Kogan B.A., et al. Effect of chronic bladder outlet obstruction on blood flow of the rabbit bladder. J Urol 165 (2001) 640-646
13. Elbadawi A., Resnick N.M., Dörsam J., Yalla S.V., and Haferkamp A. Structural basis of neurogenic bladder dysfunction. I. Methods of prospective ultrastructural study and overview of the findings. J Urol 169 (2003) 540-546
14. Tse V., Wills E., Szonyi G., and Khadra M.H. The application of ultrastructural studies in the diagnosis of bladder dysfunction in a clinical setting. J Urol 163 (2000) 535-539
15. Drake M.J., Harvey I.J., Gillespie J.I., and Van Duyl W.A. Localized contractions in the normal human bladder and in urinary urgency. BJU Int 95 (2005) 1002-1005
16. McCarthy C.J., Zabbarova I.V., Brumovsky P.R., Roppolo J.R., Gebhart G.F., and Kanai A.J. Spontaneous contractions evoke afferent nerve firing in mouse bladders with detrusor overactivity. J Urol 181 (2009) 1459-1466
17. Yokoyama O., Komatsu K., Kodama K., Yotsuyanagi S., Niikura S., and Namiki M. Diagnostic value of intravesical lidocaine for overactive bladder. J Urol 164 (2000) 340-343
18. Dinis P., Silva J., Ribeiro M.J., Avelino A., Reis M., and Cruz F. Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: a pilot study. Eur Urol 46 (2004) 88-94
19. Vlaskovska M., Kasakov L., Rong W., et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci 21 (2001) 5670-5677
20. Cockayne D.A., Hamilton S.G., Zhu Q.M., et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407 (2000) 1011-1015
21. Steers W.D., Kolbeck S., Creedon D., and Tuttle J.B. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 88 (1991) 1709-1715
22. Charrua A., Pinto R., Frias B., Cruz C.D., and Cruz F. TRPV1 expression in the bladder is essential for NGF-induced detrusor overactivity. Neurourol Urodynam 28 (2009) 99 abstract
23. Steers W.D. Rat: overview and innervation. Neurourol Urodyn 13 (1994) 97-118
24. Balkau B., and Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetes Med 16 (1999) 442-443
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
26. Makhsida N., Shah J., Yan G., Fisch H., and Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 174 (2005) 827-834
27. Meigs J.B. Epidemiology of the metabolic syndrome. Am J Manag Care 8 Suppl (2002) S283-S292
28. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., Pyorala K., and DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164 (2004) 1066-1076
29. Moebus S., Hanisch J.U., Aidelsburger P., Bramlage P., Wasem J., and Jöckel K.H. Impact of 4 different definitions used for the assessment of the prevalence of the metabolic syndrome in primary healthcare: the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 6 (2007) 22
30. Maggio M., Lauretani F., Ceda G., et al. Estradiol and metabolic syndrome in older Italian men: the InCHIANTI study. J Androl 31 (2010) 155-162
31. Knoblovits P, Pablo R. Costanzo PR, et al. Erectile dysfunction, obesity, insulin resistance, and their relationship with testosterone levels in eugonadal patients in an andrology clinic setting. J Androl. In press. doi:10.2164/jandrol.109.007757.
32. Bal K., Oder M., Sahin A.S., et al. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology 69 (2007) 356-360
33. Hammarsten J., and Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39 (2001) 151-158
34. Ozden C., Ozdal O.L., Urgancioglu G., Koyuncu H., Gokkaya S., and Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51 (2007) 199-206
35. Kaplan S., Fisch H., and Berriman S.J. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms, sexual dysfunction, and components of the metabolic syndrome. J Urol 177 Suppl (2007) 497-498 Abstract 1508
36. Kristal A.R., Arnold K.B., Schenk J.M., et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 177 (2007) 1395-1400
37. Desgrandchamps F., Haab F., Coloby P., Slama A., and Gaudin A.F. Instant 2006: cardio-metabolic markers in subjects with lower urinary tract symptoms in the French general population. Eur Urol Suppl 7 (2008) 130 Abstract 237
38. Gupta A., Gupta S., Pavuk M., and Roehrborn C.G. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 68 (2006) 1198-1205
39. Temml C., Obermayr R., Marszalek M., Rauchenwald M., Madersbacher S., and Ponholzer A. Are lower urinary tract symptoms influenced by metabolic syndrome?. Urology 73 (2009) 544-548
40. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291 (2004) 2978-2984
41. Platz E.A., Kawachi I., Rimm E.B., et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med 158 (1998) 2349-2356